Axcella’s AXA Candidates are comprised of unique compositions of Endogenous Metabolic Modulators with the goal of addressing multiple drivers of healthy metabolic function or dysregulation for use in either consumer health† or drug products.
†As used on this website, consumer health product means conventional food or dietary supplement
Our innovative paradigm integrates preclinical and IRB-reviewed, Non-IND clinical studies to understand the impact of AXA candidates on human biology. Our platform has already produced a rich pipeline of AXA candidates in muscle, liver and CNS*.
*Axcella conducts Non-IND, IRB-approved food studies to evaluate the safety and tolerability of its AXA candidates in human subjects, or effects on the normal structure or function of the body. Studies intended to directly support drug development will be conducted under an IND.
AXA candidates are designed to leverage the diversity of amino acids and the fundamental role they play in metabolic biology, and have the potential to support the normal metabolic structure and function of the body and restore health across a network of dysregulated pathways.
